DuPont de Nemours Business Summary

DuPont de Nemours, Inc. (DD) operates as a premier specialty materials provider, generating revenue through the high-margin sale of advanced polymers, chemicals, and technology-based solutions to global B2B markets. Following the strategic 2025 spin-off of its electronics business into Qnity Electronics and the 2026 divestiture of its Aramids unit, the company’s business model is concentrated into two core segments: Healthcare & Water Technologies and Diversified Industrials. These segments focus on high-growth applications such as medical packaging, biopharma processing, industrial water filtration, and next-generation automotive components. DuPont competes primarily against 3M, Dow Inc., and Eastman Chemical Company, positioning itself as a leaner, less cyclical specialty player with a projected 2026 revenue of approximately $7.1 billion and a strategic emphasis on high-vitality product innovation. Originally founded in 1802 by Eleuthère Irénée du Pont, the modern iteration of the company is led by Chief Executive Officer Lori Koch, who previously served as CFO and was a key architect of the firm’s recent portfolio transformation. The executive team includes CFO Antonella Franzen, CTO Marty DeGroot, and segment presidents Jeroen Bloemhard (Healthcare & Water) and Beth Ferreira (Diversified Industrials). The board is chaired by Edward D. Breen, the former CEO widely recognized for leading the DowDuPont merger and subsequent three-way split. Notable board members include D.G. Macpherson (Chairman and CEO of W.W. Grainger, Inc.), who joined in early 2026, and Amy G. Brady (CIO of KeyCorp), reflecting a leadership pedigree deeply rooted in industrial scale, financial discipline, and digital transformation.